What should be the basis for starting non-metastatic CRPC patients on one of the novel anti-androgens?
At the 2019 annual meeting of the American Urological Association (AUA), Dr Jarrard was a member of the instructional faculty in a session titled “AUA Castration Resistant Prostate Cancer (CRPC) Guidelines and Therapeutic Advances in Metastatic Prostate Cancer.”
Expert perspective on some of the important developments in prostate cancer management from the AUA 2019 meeting.
Is testosterone replacement in men with prostate cancer safe?
Should brachytherapy be used more than it is for localized prostate cancer?
What are the adverse effects related to the use of medications for advanced prostate cancer?
What is the best approach for treating patients with cT4 prostate cancer?
What is the role of race in prostate cancer treatment decisions?
Is there a place for active surveillance in the management of men with intermediate-risk prostate cancer?
When is it appropriate to use adjuvant radiation in patients with high-risk pathology instead of waiting for PSA to rise?
What is the top goal of ureteroscopy (URS)?
What is the take home message from the various presentations at this year’s AUA annual meeting?
What clinical/laboratory findings identify men for whom MRI scans are appropriate?
Should biomarker assays be an integral part of prostate cancer patient care?
What are the major challenges regarding focal therapy for prostate cancer?
What have you learned about the differences in tolerability of the newer agents, adverse event profiles, and cost?